Original Article
DOI: https://doi.org/10.70749/ijbr.v3i1.583

INDUS JOURNAL OF BIOSCIENCE RESEARCH
https://induspublishers.com/IJBR
ISSN: 2960-2793/ 2960-2807

Personalized Cancer Therapy: Advancement in Biomarker-Based Treatment Strategies for Non-Small Cell Lung Cancer

Ubaid Ur Rehman[1], Quratulain Badar[2], Yasser Hijazi Abdoon[3], Muhammad Ghous[4], Tahir Aslam[5], Minahal Aslam[6], Syed Rizvan Ali[7]

[1]North Surgical Ward, Mayo Hospital Lahore/King Edward Medical University, Lahore, Punjab, Pakistan.
[2]Department of Oncology, Ziauddin University and Hospital, Karachi, Sindh, Pakistan.
[3]Osman, Sudan medical Specialization Board, Sudan.
[4]Department of biochemistry, Minhaj University, Lahore, Punjab, Pakistan.
[5]Department of Thoracic Surgery, Fatima Jinnah Institute of Chest Diseases, Quetta, Balochistan, Pakistan.
[6]Quaid-e-Azam University, Islamabad, Pakistan.
[7]Institute of Biochemistry and Biotechnology, University of Veterinary and Animal Sciences, Lahore, Punjab, Pakistan.

ARTICLE INFO

Keywords

Non-Small Cell Lung Cancer, EGFR mutations, ALK rearrangements, PD-L1 expression, Personalized Therapy, Targeted Therapy, Immunotherapy, Biomarker Testing, Progression-Free Survival.

Corresponding Author: Ubaid Ur Rehman,
North Surgical Ward, Mayo Hospital Lahore/King Edward Medical University, Lahore, Punjab, Pakistan.
Email: drubaid@live.com

Declaration

Author's Contributions: All authors equally contributed to the study and approved the final manuscript.

Conflict of Interest: No conflict of interest.

Funding: No funding received by the authors.

Article History

Received: 11-10-2024
Revised: 05-01-2025
Accepted: 20-01-2025

ABSTRACT

This study sought to assess the effectiveness of biomarker-directed personalized therapies for the treatment of non-small cell lung cancer (NSCLC) targeting actionable genetic mutations like EGFR, ALK, and PD-L1. A prospective observational study was performed on 200 NSCLC patients with established genetic alterations, divided into four groups: EGFR-mutant, ALK-rearranged, PD-L1-positive, and wild-type (no biomarkers). Patients were treated with targeted therapies (e.g., EGFR inhibitors, ALK inhibitors, PD-1 inhibitors) or platinum-based chemotherapy. EGFR-mutant patients had the best response rates (70%) and overall survival (OS) of 24 months. ALK-rearranged and PD-L1-positive patients also had good outcomes, with response rates of 65% and 60%, respectively, and OS of 22 and 20 months. In contrast, the wild-type group had the worst response rate (45%) and OS (16 months). The study also found significantly fewer adverse events in the EGFR and ALK treatment groups than with chemotherapy. Kaplan-Meier analysis indicated better progression-free survival (PFS) in the biomarker-targeted groups. Statistical analysis using ANOVA and chi-square tests proved significant differences in response rates (p-value < 0.05), validating the effectiveness of biomarker-directed personalized treatment approaches. These findings suggest that biomarker-directed therapies can significantly enhance patient outcomes compared to standard chemotherapy, highlighting the value of biomarker testing in clinical practice.

INTRODUCTION

Personalized cancer treatment, also referred to as precision medicine, has become a revolutionary leap in oncology, providing more effective and personalized treatment options. This is in contrast to conventional cancer treatments, which adopt a "one-size-fits-all" approach by employing standardized chemotherapy protocols that are of limited effectiveness and have severe side effects. In the scenario of non-small cell lung cancer (NSCLC), one of the most common causes of cancer mortality worldwide, conventional treatments have been met with only modest success. NSCLC is responsible for approximately 85% of lung cancer, and despite surgery, chemotherapy, and radiation, survival rates for patients with advanced-stage disease are abysmal. The increasing incidence of NSCLC necessitates novel treatment approaches to enhance outcomes and improve survival rates. The incorporation of biomarker-based therapies into clinical practice has heralded a new era of cancer treatment, where therapies are personalized based on the unique genetic and molecular changes occurring in the tumor [1].

Biomarkers, which are quantifiable molecules in blood, tissue, or tumor, are pivotal in the diagnosis, prognosis, and treatment of cancer. For NSCLC, a series of genetic alterations and molecular markers, including epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and ROS1 rearrangements, have emerged as central drivers of tumor progression. These molecular changes are valuable for understanding the biological behavior of tumors and for enabling the design of targeted therapies that target the root molecular defects causing the cancer [2]. Targeted therapies, such as tyrosine kinase inhibitors (TKIs) for EGFR mutations and ALK inhibitors, have transformed the treatment landscape for NSCLC, offering patients more effective and less toxic alternatives to traditional chemotherapy [3]. The ability to personalize cancer treatment based on these molecular profiles not only improves the precision of therapy but also minimizes the adverse effects commonly associated with chemotherapy, such as nausea, hair loss, and fatigue.

Immunotherapy is another major breakthrough in the treatment of cancer, especially for NSCLC. In the last decade, immune checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 antibodies, have demonstrated significant clinical benefits in patients with advanced-stage NSCLC. These therapies work by unleashing the body's immune system to recognize and attack cancer cells more effectively. PD-1 inhibitors, such as pembrolizumab and nivolumab, have shown impressive effectiveness in the treatment of patients with tumors that are highly positive for PD-L1. Their approval has dramatically improved the survival rates of patients with previously untreatable, metastatic NSCLC [4]. The use of immune checkpoint inhibitors in combination with other therapies, including chemotherapy and targeted treatments, is also being explored to enhance therapeutic outcomes and overcome resistance mechanisms that may limit the effectiveness of single-agent immunotherapy [5].

Despite the revolutionary changes brought about by biomarker-based treatments and immunotherapies, there are still many challenges in NSCLC. One of the major problems is the development of resistance to targeted therapies, as the tumor can adapt and acquire new mutations that render the treatment less effective. For instance, in the case of EGFR-mutant NSCLC, secondary mutations like T790M can develop in tumors, making them resistant to first-line EGFR inhibitors [6]. Additionally, not every patient has actionable mutations, and the identification of novel biomarkers remains in an ongoing area of research. The pursuit of additional predictive biomarkers and a better understanding of the tumor microenvironment are critical to take personalized treatment strategies a step further. Additionally, new technologies like liquid biopsy and next-generation sequencing allow for real-time monitoring of tumor evolution and offer a non-invasive method to detect mutations, thereby offering a more dynamic and personalized approach to treatment [7].

One of the biggest challenges for personalized medicine would be accessibility and affordability, with advanced therapies. Targeted therapies and immunotherapies are usually expensive, or they cost a lot to treat, and that limits the treatment to those patients- they are mainly also mostly unaffordable in the low-resource settings. The infrastructure and capability required to routinely practice biomarker testing and molecular profiling in every clinical setting will need to be established within health systems; each patient needs to have the best care [8]. So, while the progress in biomarker-based treatment strategies for NSCLC has indeed been revolutionary, further study, clinical trials, and policy reforms are crucial to ensure that these innovative therapies can be supported for as wide a population as possible.

It would analyze recent advances in the field of NSCLC by biomarkers that describe the evolution from the search for key molecular alterations to develop targeted therapies and immunotherapies with challenges and opportunities in applying these personalized regimens. A systematic review in an attempt to depict the near horizon direction of future changes based on the contemporary face of precision in cancer treatment by identifying present areas for improvement with promises of patient's outcomes [9].

Personalized Cancer Therapy

Personalized cancer therapy, also known as precision medicine, has significantly reshaped the treatment landscape in oncology. This approach aims to tailor treatment regimens based on the individual molecular profile of a patient’s cancer, offering a more targeted and effective strategy compared to traditional "one-size-fits-all" treatments [10]. The application of personalized therapy is particularly important in the case of non-small cell lung cancer (NSCLC), a highly prevalent and often fatal form of lung cancer. NSCLC represents approximately 85% of all lung cancer diagnoses and continues to be a leading cause of cancer-related deaths worldwide. Traditional treatment methods, such as chemotherapy and radiation, are still widely used but often come with substantial side effects and limited efficacy, especially in advanced stages of the disease. The development of biomarker-based therapies has become a critical turning point in NSCLC treatment, improving patient outcomes and offering more effective alternatives to conventional therapies [11].

Role of Biomarkers in NSCLC Diagnosis and Treatment

Biomarkers are measurable molecules that can provide essential information regarding the presence of cancer,

its progression, and response to treatment. In NSCLC, a variety of genetic mutations and molecular alterations have been identified as key drivers of the disease. Some of the most well-known biomarkers include mutations in the epidermal growth factor receptor (EGFR), rearrangements of anaplastic lymphoma kinase (ALK), and the presence of ROS1 rearrangements. The identification of these biomarkers allows for the development of targeted therapies that specifically inhibit the molecular pathways driving cancer cell proliferation and survival [12]. Targeted therapies, such as EGFR inhibitors (e.g., gefitinib, erlotinib) and ALK inhibitors (e.g., crizotinib, alectinib), have revolutionized the treatment of NSCLC by providing more effective options with fewer side effects compared to conventional chemotherapy [13].

In addition to improving the precision of treatment, biomarkers also provide insights into prognosis and the likelihood of treatment success. By analyzing a patient's tumor at the molecular level, clinicians can predict which treatments are most likely to be effective, sparing patients from ineffective therapies and reducing unnecessary toxicity [14]. Biomarker testing is now a routine part of NSCLC diagnosis and treatment planning, making it possible to personalize therapy based on the unique genetic makeup of the tumor.

Immunotherapy: A New Frontier in NSCLC Treatment

Immunotherapy has emerged as one of the most promising advancements in personalized cancer therapy. For NSCLC patients, immune checkpoint inhibitors have shown significant success in treating advanced and metastatic disease, particularly those who do not respond well to traditional treatments. Drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo), which target the PD-1/PD-L1 pathway, have demonstrated substantial benefits in clinical trials, leading to improved survival outcomes for patients with high PD-L1 expression in their tumors [15]. These therapies work by blocking the immune checkpoint proteins that prevent T-cells from recognizing and attacking cancer cells. By unleashing the body's immune system, these inhibitors enable the immune system to mount a stronger and more effective anti-cancer response [16].

Immunotherapy's role in NSCLC treatment is not limited to PD-1 inhibitors alone. In recent years, combination therapies that pair immune checkpoint inhibitors with chemotherapy or targeted therapies have gained attention, as they have shown to enhance treatment efficacy and overcome resistance mechanisms. Combining immunotherapy with other modalities represents a promising strategy to extend the benefits of personalized cancer therapy to a broader range of NSCLC patients [17]

Challenges and Limitations in Personalized NSCLC Therapy

Despite the tremendous progress made in personalized cancer therapy for NSCLC, several challenges persist. One of the primary concerns is the development of resistance to targeted therapies. Over time, tumors may acquire secondary mutations that render initial treatments ineffective. For example, patients with EGFR-mutant NSCLC may develop a resistance mutation like T790M, which reduces the efficacy of EGFR tyrosine kinase inhibitors (TKIs) [18]. This resistance highlights the need for continuous monitoring and the development of next-generation therapies to overcome such challenges. Additionally, not all NSCLC patients have actionable mutations, and there is still a gap in the identification of other potential biomarkers that can guide treatment decisions. The detection of rare mutations and the understanding of the tumor microenvironment remain areas of active research. Liquid biopsy techniques, which analyze tumor DNA circulating in the blood, have emerged as a promising tool for real-time tracking of tumor mutations and monitoring of therapeutic responses, potentially allowing for more dynamic and personalized treatment regimens [19]. Another barrier to the widespread implementation of biomarker-based therapies is the cost. Many of the most effective therapies, particularly immunotherapies and targeted drugs, come with high treatment costs, which may not be accessible to all patients, particularly in resource-limited settings. Furthermore, not all healthcare systems are equipped with the necessary infrastructure to support comprehensive molecular testing and personalized treatment planning, which further complicates the widespread adoption of these therapies [20].

Research Objectives

The main research objectives of the study are;

- To identify key biomarkers in NSCLC and their impact on therapy selection.
- To evaluate the effectiveness of targeted therapies and immunotherapies in biomarker-driven NSCLC treatment.
- To assess the challenges in implementing personalized therapies, focusing on resistance, cost, and accessibility.

Problem Statement

NSCLC is a significant cause of death from cancer all over the world. Advanced patients with this condition have limited options and poor prognoses. The mainstay therapies are chemotherapy and radiation, and most of them lack potency with numerous side effects. Many patients have been left behind in response to available therapies due to tumor heterogeneity and drug resistance. Biomarker-based treatments, including targeted therapies and immunotherapies, offer a possibility to

tailor therapies for patients as a result of their individual biomarker status. This may provide treatment options that improve patient outcomes. However, certain barriers exist, such as the identification of actionable biomarkers, high costs associated with these therapies, and the accessibility of biomarker testing in NSCLC treatment.

Significance of the Study

This study is important for advancing knowledge in the fields of personalized cancer therapy in the NSCLC due to its focus on the aspects of biomarkers in decisions regarding the treatment process. Through analyses of targeted therapies and immunotherapies, the research would help identify more effective and more targeted treatment procedures, thereby improving survival rates for patients suffering from NSCLC. It will address issues related to drug resistance and affordability, offering insights on overcoming barriers for biomarker-based therapies to gain more widespread use in clinical settings. This will be associated with improved clinical outcomes and better quality of life for patients.

LITERATURE REVIEW

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality globally, with a limited prognosis for patients diagnosed at advanced stages. Historically, treatment options for NSCLC were primarily based on chemotherapy, radiation therapy, and surgery. However, these conventional treatments often fail to address the molecular complexity and heterogeneity of the disease. Over the past decade, personalized cancer therapy has emerged as a more targeted and effective approach to treating NSCLC [15]. Personalized therapy, also known as precision medicine, uses biomarkers to identify specific genetic mutations or molecular alterations within the tumor, enabling clinicians to select therapies that are most likely to be effective for each individual patient [21]. This advancement has paved the way for therapies that specifically target the molecular drivers of NSCLC, enhancing treatment efficacy while minimizing toxic side effects typically seen with traditional chemotherapy [22].

The foundation of personalized therapy in NSCLC lies in the identification of key genetic mutations and molecular alterations that drive tumor progression. Over the years, several genetic mutations have been identified as crucial in the pathogenesis of NSCLC [23]. Among the most significant are mutations in the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1, and KRAS genes. These mutations are found in a subset of NSCLC patients and are associated with aggressive tumor growth and poor prognosis if left untreated [24].

EGFR mutations, present in approximately 10-15% of Caucasian NSCLC patients and 30-50% of Asian patients, are one of the well-studied biomarkers. Patients with EGFR mutations often benefit from EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and osimertinib, which specifically target and inhibit the mutant EGFR protein, preventing downstream signaling pathways that promote cancer cell survival [25]. Similarly, ALK rearrangements are observed in approximately 3-7% of NSCLC patients and have led to the development of ALK inhibitors such as crizotinib and alectinib, which have significantly improved patient outcomes [26]. ROS1 rearrangements, another key alteration, affect a smaller subset of patients but can also be targeted with ROS1 inhibitors, further highlighting the precision offered by biomarker-driven therapies in NSCLC [27].

Targeted Therapies: Impact on NSCLC Treatment

Targeted therapies have revolutionized the treatment of non-small cell lung cancer by focusing on the specific genetic and molecular alterations that drive the cancer. Unlike traditional chemotherapy, which broadly targets all rapidly dividing cells, targeted therapies aim to inhibit specific molecules that contribute to the growth and survival of cancer cells [28]. These therapies had significantly better patient clinical outcomes. They are even more targeted treatments and less dangerous than traditional interventions. As the nature of NSCLC has more and more deeply been understood with respect to specific molecular alterations and markers, targeted therapies have indeed become a larger part of what is used to medically manage the patient's disease with mutations in their genes, in particular, regarding EGFR mutation and ALK mutation [29].

The role of EGFR mutations in NSCLC has been extensively studied, particularly in relation to the use of EGFR tyrosine kinase inhibitors (TKIs). EGFR mutations, which are present in about 10-15% of Caucasian NSCLC patients and a higher proportion of Asian patients, are associated with oncogenic transformation and tumor progression. These mutations occur most commonly in exon 19 deletions and exon 21 L858R point mutations, leading to dysregulated EGFR signaling and unchecked cell proliferation [30].

First-generation EGFR TKIs, such as gefitinib and erlotinib, revolutionized the treatment of EGFR-mutant NSCLC by specifically targeting the mutant EGFR protein and inhibiting downstream signaling pathways responsible for tumor growth. The clinical efficacy of these drugs was demonstrated in large-scale randomized clinical trials, such as the IPASS trial (International Pharmacologic Study of NSCLC), which showed that gefitinib improved progression-free survival (PFS) in EGFR-mutant patients when compared to traditional chemotherapy [31]**.** These results were significant in showing that EGFR-targeted therapy could offer

superior efficacy over chemotherapy, especially in patients with activating EGFR mutations.

However, resistance to first-generation EGFR inhibitors, particularly due to the T790M mutation in exon 20, has posed a significant challenge in long-term management. This mutation alters the binding affinity of EGFR TKIs, rendering them ineffective. In response, second-generation EGFR TKIs, such as afatinib, and third-generation inhibitors like osimertinib have been developed to overcome this resistance [32]. Osimertinib, in particular, has shown promising results in clinical trials, such as the AURA3 trial, where it demonstrated superior efficacy compared to platinum-based chemotherapy in patients with T790M-positive resistance mutations [33]. Osimertinib selectively targets both the original activating EGFR mutations and the T790M resistance mutation, offering durable clinical responses and improved overall survival, thus establishing itself as a standard treatment for EGFR-mutant NSCLC with acquired resistance.

The discovery of ALK gene rearrangements in NSCLC patients has led to the development of ALK inhibitors, another class of targeted therapies. These rearrangements, present in about 3-7% of NSCLC cases, lead to the fusion of the ALK gene with other genes, resulting in abnormal ALK protein activity that drives tumor growth. Crizotinib, the first ALK inhibitor approved for clinical use, showed remarkable efficacy in treating patients with ALK-positive NSCLC, particularly in patients with advanced or metastatic disease. In the pivotal PROFILE 1007 trial, crizotinib demonstrated superior progression-free survival compared to traditional chemotherapy in patients with ALK-positive NSCLC [34]. This marked a significant milestone in targeted therapy, as it provided an effective treatment option for a subset of NSCLC patients who had few alternatives.

However, as with EGFR mutations, resistance to ALK inhibitors often develops. The most common mechanism of resistance to crizotinib involves the secondary mutations in the ALK gene, such as L1196M and G1202R, which reduce the drug's ability to bind to the ALK fusion protein. To overcome this resistance, second-generation ALK inhibitors like ceritinib, alectinib, and brigatinib have been developed. Studies have shown that these newer inhibitors are effective in patients who develop resistance to crizotinib, with alectinib particularly showing a better safety profile and effectiveness against brain metastases. For example, the ALEX trial demonstrated that alectinib significantly improved progression-free survival compared to crizotinib, making it a preferred option for ALK-positive NSCLC patients [34].

Moreover, third-generation ALK inhibitors, such as lorlatinib, have shown promising results in patients who experience resistance to both first- and second-generation ALK inhibitors. The CROWN trial highlighted lorlatinib's ability to delay disease progression in ALK-positive patients, providing hope for managing this subgroup of NSCLC even in later stages of treatment.

Combination Therapies and Overcoming Resistance

Despite the strides in targeted therapy for EGFR- and ALK-mutant NSCLC, overcoming resistance to treatment is still the major challenge. Therefore, combination therapies have been studied by researchers as ways of overcoming resistance and offering better patient outcomes. Combination strategies commonly combine targeted therapy with other modes of treatment, like chemotherapy, immunotherapy, or other targeted drugs, to address the cancer through various angles.

For instance, the combination of EGFR TKIs with chemotherapy has been explored in clinical trials. In the IMPRESS trial, the addition of chemotherapy to gefitinib did not show improved outcomes over gefitinib alone, suggesting that chemotherapy may not always add significant benefit to EGFR-mutant NSCLC patients [35]. However, the combination of targeted therapies with immunotherapy has garnered increasing attention. Combining EGFR inhibitors with immune checkpoint inhibitors may enhance antitumor immunity by reactivating immune responses suppressed by the tumor microenvironment. Early-phase clinical trials are investigating the potential synergistic effects of this combination approach in EGFR-mutant NSCLC patients. Similarly, in the case of ALK inhibitors, research is ongoing to combine these therapies with other agents to overcome resistance and enhance the durability of responses. The combination of ALK inhibitors with MEK inhibitors, which target a critical part of the MAPK pathway often activated in ALK-positive cancers, has shown promising results in preclinical studies and early-phase clinical trials [36]. These combination therapies may play a pivotal role in improving long-term control of the disease and preventing relapse due to resistance.

Immunotherapy: A New Paradigm in NSCLC Treatment

Immunotherapy represents a significant shift in the treatment of non-small cell lung cancer (NSCLC), offering a fundamentally different approach compared to traditional therapies such as chemotherapy and radiation. Whereas chemotherapy targets rapidly dividing cancer cells in a broad and often indiscriminate manner, immunotherapy works by stimulating the body's immune system to specifically recognize and eliminate cancer cells. This personalized approach holds promise for patients who have limited treatment options, particularly those with advanced or metastatic disease. One of the most exciting classes of immunotherapeutic

agents to emerge is immune checkpoint inhibitors, which focus on overcoming the mechanisms tumors use to evade immune surveillance. Among these, inhibitors of the PD-1 (Programmed Cell Death Protein 1) receptor and its ligand, PD-L1, have become cornerstone treatments in advanced NSCLC [37].

The PD-1/PD-L1 pathway is a critical immune checkpoint involved in regulating the immune response. PD-1 is a receptor present on the surface of T-cells, which are a key component of the immune system responsible for attacking foreign or abnormal cells, such as cancer cells. Under normal circumstances, when T-cells encounter the PD-L1 ligand, typically expressed on tumor cells and other cells within the tumor microenvironment, the interaction suppresses the T-cell's activity, preventing it from attacking the tumor. This interaction is one of the ways tumors evade immune detection and destruction. By inhibiting the PD-1 receptor (using agents like pembrolizumab (Keytruda) and nivolumab (Opdivo)) or its ligand PD-L1 (using agents like atezolizumab (Tecentriq)), immune checkpoint inhibitors block this suppression, allowing the immune system to more effectively target and kill cancer cells.

This inhibition of the PD-1/PD-L1 pathway has shown substantial promise in the treatment of NSCLC. Clinical studies have demonstrated that PD-1 inhibitors, when used alone or in combination with chemotherapy, can significantly improve overall survival and progression-free survival in patients with advanced-stage NSCLC, especially those with high PD-L1 expression on their tumors. Pembrolizumab, for example, has been shown to offer superior outcomes in terms of survival when compared to traditional chemotherapy, particularly in patients whose tumors exhibit high levels of PD-L1 expression. This has led to the FDA approval of pembrolizumab as a first-line treatment for NSCLC, marking a significant milestone in the treatment of this disease.

One of the key challenges in immunotherapy is determining which patients are most likely to benefit from treatment. While PD-1 inhibitors have shown clinical benefit across a broad range of NSCLC patients, the expression of PD-L1 on tumor cells has emerged as a critical biomarker for predicting the likelihood of a favorable response to PD-1/PD-L1 inhibitors. Studies have shown that tumors with higher levels of PD-L1 expression are more likely to respond to treatment with immune checkpoint inhibitors. As a result, PD-L1 testing has become a routine part of the diagnostic workup for NSCLC, helping guide treatment decisions [38].

However, PD-L1 expression is not the only determinant of response to immunotherapy. Some patients with low or absent PD-L1 expression may still experience significant benefit from immune checkpoint inhibitors, suggesting that additional factors beyond PD-L1 may influence treatment outcomes. Conversely, not all patients with high PD-L1 expression respond well to treatment, highlighting the complexity of immune response and the need for more refined biomarkers. Researchers are actively exploring combination therapies and novel immune targets to improve the effectiveness of immunotherapy, as well as to address cases where patients show initial resistance to treatment.

Despite the initial successes of immunotherapy, a major challenge in the clinical application of PD-1/PD-L1 inhibitors is the development of resistance. While some patients experience long-lasting responses, others may develop resistance over time, leading to disease progression. Resistance to immunotherapy can occur through several mechanisms, such as the loss of PD-L1 expression on tumor cells, mutations in the JAK-STAT signaling pathway, or alterations in the tumor microenvironment that inhibit immune activation. In some cases, tumors can upregulate other immune checkpoint molecules, such as CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4), which further suppress T-cell activity and render immune checkpoint inhibitors less effective [38].

To overcome these limitations, researchers are investigating combination therapies, which aim to target multiple immune checkpoint pathways or combine immunotherapy with other modalities, such as chemotherapy, targeted therapies, or radiation therapy. Early-phase clinical trials have shown that combining PD-1 inhibitors with chemotherapy or anti-CTLA-4 antibodies can lead to improved clinical responses, suggesting that combination strategies may be a way forward in overcoming resistance and enhancing the effectiveness of immunotherapy in NSCLC [29]. Another area of interest is the exploration of biomarker-driven combination approaches, where the addition of other immune-modulatory agents is tailored to the patient's specific tumor profile.

The future of immunotherapy in NSCLC treatment looks promising, with continued research focused on optimizing existing therapies and identifying new treatment strategies. The ongoing development of next-generation immune checkpoint inhibitors that target alternative immune checkpoints (e.g., LAG-3, TIM-3, and TIGIT) could provide additional avenues for treatment, particularly for patients who do not respond to current PD-1/PD-L1 inhibitors [14]. Moreover, the integration of personalized medicine with immunotherapy, through techniques such as next-generation sequencing (NGS) and liquid biopsy, offers the potential to better predict which patients will benefit from specific therapies and to monitor their treatment response in real-time [39].

The role of adjuvant immunotherapy is another area of active investigation. While immune checkpoint inhibitors have proven successful in metastatic NSCLC, recent trials are exploring the use of these therapies in the adjuvant setting—before recurrence in early-stage disease. If these trials are successful, immunotherapy could become a key component in the treatment of early-stage NSCLC, potentially preventing recurrence and improving long-term survival rates. Additionally, the use of neoantigen-based vaccines to stimulate a patient's immune system to recognize and target tumor-specific antigens is being investigated as a potential new therapeutic approach, further expanding the repertoire of immunotherapeutic options in NSCLC.

While personalized therapies offer significant promise in improving NSCLC treatment outcomes, several challenges and limitations remain. One of the primary concerns is the development of resistance to targeted therapies and immunotherapy. As tumors evolve and acquire secondary mutations or adapt to new environmental conditions, they can bypass the effects of initially effective treatments. For example, resistance to EGFR TKIs may occur due to the emergence of the T790M mutation, or in the case of ALK inhibitors, resistance can develop due to mutations like L1196M or G1202R. Similarly, immune evasion mechanisms can lead to resistance to PD-1 inhibitors.

Another challenge is the cost of personalized cancer therapies. Many of the most effective therapies, such as targeted treatments and immune checkpoint inhibitors, are expensive, which may limit access for some patients, particularly in low- and middle-income countries. Additionally, biomarker testing required to guide personalized treatment decisions is often costly and may not be accessible in all clinical settings. Even in resource-rich environments, not all patients may be able to afford the necessary testing or therapy.

Lastly, there is an ongoing need for the identification of new actionable biomarkers to guide treatment decisions. While significant progress has been made with EGFR, ALK, and PD-L1, a large proportion of NSCLC patients still do not have identified mutations that can be targeted effectively. Advances in liquid biopsy and next-generation sequencing (NGS) technologies are enabling more dynamic and real-time monitoring of tumor evolution, but these techniques need to be more widely implemented and standardized to be effective in clinical practice [40].

The future of personalized therapy in NSCLC is promising, with ongoing research focused on overcoming current limitations and expanding treatment options. Strategies being explored include the development of next-generation targeted therapies that can overcome resistance, the identification of new biomarkers that may predict response to therapy, and the use of combination therapies to increase efficacy and prevent resistance. Advances in liquid biopsy are expected to play a pivotal role in monitoring tumor evolution and guiding treatment decisions in real time.

Additionally, the integration of artificial intelligence (AI) and machine learning into clinical practice could help in identifying novel biomarkers, predicting treatment responses, and optimizing personalized treatment regimens. Furthermore, the ongoing exploration of immunotherapy combinations, such as combining PD-1 inhibitors with other immune-modulatory agents or targeted therapies, could further enhance therapeutic outcomes in NSCLC.

METHODOLOGY

Study Design

This was a prospective observational study designed to determine the effect of biomarker-driven, personalized treatments in NSCLC patients. The focus of the study included patients with actionable genetic mutations (e.g., EGFR, ALK, and PD-L1). The target was to assess the clinical outcomes between targeted therapies, including EGFR inhibitors, ALK inhibitors, and immunotherapies, like PD-1 inhibitors, in comparison to standard chemotherapy.

Study Population

Inclusion Criteria

- Adult patients (≥18 years) diagnosed with stage IIIB-IV NSCLC.
- Positive biomarker tests for EGFR mutations, ALK rearrangements, or PD-L1 expression.
- ECOG performance status 0-2.
- Capability for informed consent.

Exclusion Criteria

- Patients with severe comorbidities or prior treatment with the same class of therapies.
- Pregnant or breastfeeding women.

Biomarker Testing

All enrolled patients underwent biomarker testing to assess specific mutations and expressions. EGFR mutation testing was conducted using either NGS or PCR. ALK rearrangement testing was performed through FISH or NGS. Additionally, PD-L1 expression was tested using IHC.

Treatment Protocols

For patients with EGFR mutations, first-line treatment was initiated with EGFR TKIs such as gefitinib or osimertinib. ALK inhibitors like crizotinib or alectinib were administered to patients with ALK rearrangements. Patients who were PD-L1 positive received PD-1 inhibitors (e.g., pembrolizumab, nivolumab), either alone or in combination with chemotherapy. For patients with wild-type (no biomarkers), standard chemotherapy (e.g., platinum-based) was the prescribed treatment.

Outcome Measures

Primary Outcomes:

Overall Survival (OS) was measured as the time from the start of treatment to death. Progression-Free Survival (PFS) was defined as the time from treatment initiation until disease progression or death.

Secondary Outcomes

Response Rate (RR) was calculated as the percentage of patients showing a complete or partial response to the treatment. Quality of Life (QoL) was assessed using validated questionnaires such as the EORTC QLQ-C30. Safety was evaluated by monitoring the frequency and severity of adverse events, using the CTCAE criteria.

Data Collection & Analysis

Data Collection

Patients were regularly monitored with follow-up visits every 3 months. During these visits, imaging (CT scans) and lab tests were performed. Biomarker levels were rechecked at each follow-up to assess changes over time.

Statistical Analysis

Continuous variables, like age and survival, were compared by use of t-tests or ANOVA. Categorical variables, such as treatment response, were compared using chi-square tests. Kaplan-Meier survival analysis was used to estimate PFS and OS. The Cox proportional hazards model was applied in order to adjust for confounding factors. A p-value of < 0.05 was considered statistically significant.

Ethical Considerations

Ethical approval for the study was obtained from an institutional review board (IRB). All participants were required to sign informed consent forms. Patient confidentiality was maintained in compliance with both local and international ethical guidelines, including the Declaration of Helsinki.

Limitations

The study results were limited by sample size, especially for rare biomarkers. Additionally, the focus on advanced-stage NSCLC may have restricted the generalizability of the findings to earlier stages of the disease.

The study spanned 24 months, with the first 6 months dedicated to patient enrollment, followed by 18 months for follow-up and data analysis.

Data Analysis

Table1

Data Analysis Table (ANOVA Statistics)

Outcome Measures	Group 1: EGFR Mutations	Group 2: ALK Rearrangements	Group 3: PD-L1 Positive	Group 4: Wild-type (No Biomarkers)	F-Statistic	P-Value	Interpretation
Overall Survival (OS)	24 months	20 months	22 months	18 months	5.6	0.004	Significant difference in OS between groups. EGFR mutations showed the highest OS.
Progression-Free Survival (PFS)	15 months	12 months	14 months	10 months	3.9	0.03	Statistically significant differences in PFS. EGFR mutations delayed progression longer.
Response Rate (RR)	70%	65%	60%	45%	4.2	0.02	Significant difference in RR. EGFR group had the highest response rate.
Quality of Life (QoL)	85	80	83	75	2.6	0.06	No statistically significant difference in QoL, though EGFR patients had the highest QoL.
Safety (Severe Adverse Events)	10%	15%	20%	25%	6.7	0.001	Significant difference in safety, with wild-type patients experiencing more severe adverse events.

The analysis reveals significant differences in treatment outcomes across the groups with actionable biomarkers. Patients with EGFR mutations exhibited the best overall survival (OS) (24 months) and progression-free survival (PFS) (15 months), demonstrating the effectiveness of targeted therapies in this group. EGFR-mutant patients also had the highest response rate (RR) (70%) and the best Quality of life (QoL) scores (85), although the difference in QoL was not statistically significant. In contrast, wild-type patients (no biomarkers) showed the lowest survival and response rates, with the highest frequency of severe adverse events (25%), likely due to the toxic effects of traditional chemotherapy. ALK-rearranged and PD-L1 positive groups had intermediate outcomes, with significant improvements over the wild-type group, but did not outperform the EGFR-mutant group. These findings highlight the superior efficacy of biomarker-driven therapies, particularly for EGFR mutations, in improving patient outcomes compared to standard chemotherapy.

Table 2

Data Analysis Table (Chi-Square Statistics) with Sample Size

Outcome Measures	EGFR Mutations (N=100)	ALK Rearrangements (N=80)	PD-L1 Positive (N=90)	Wild-type (N=70)	Chi-Square Value	P-Value	Interpretation
Response Rate (RR)	70% (70/100)	65% (52/80)	60% (54/90)	45% (31/70)	10.8	0.01	Significant difference in response rates. EGFR mutation group had the highest response rate.
Severe Adverse Events	10% (10/100)	15% (12/80)	20% (18/90)	25% (17/70)	12.3	0.002	Wild-type group had the highest incidence of severe adverse events, indicating more toxicity from chemotherapy.
Biomarker Testing Success	95% (95/100)	90% (72/80)	98% (88/90)	92% (64/70)	3.4	0.34	No significant difference in testing success across groups. All groups had high success rates in biomarker testing.

Figure 1



The Chi-Square analysis revealed significant differences in treatment outcomes among the groups. The EGFR mutation group showed the highest response rate (70%) and the lowest incidence of severe adverse events (10%), highlighting the effectiveness and better tolerability of EGFR-targeted therapies. In contrast, the wild-type group had the lowest response rate (45%) and the highest rate of severe adverse events (25%), indicating the higher toxicity of conventional chemotherapy. Although there were variations in response rates and adverse events, biomarker testing success was high and consistent across all groups, demonstrating the reliability of biomarker testing for personalized treatment strategies in NSCLC. These findings underline the importance of biomarker-driven therapies, particularly for EGFR mutations, in improving patient outcomes and reducing side effects compared to traditional chemotherapy.

Table 3

Data Analysis Table (One-Way Multiple Range Analysis - Tukey's HSD Test)

Group	Mean Response Rate (RR)	Mean Severe Adverse Events	Mean Overall Survival (OS)	Comparison	P-Value	Interpretation
EGFR Mutations (N=100)	70%	10%	24 months	EGFR vs. ALK, PD-L1, Wild-type	0.01	EGFR mutation showed the highest response rate and best survival.
ALK Rearrangements (N=80)	65%	15%	22 months	ALK vs. Wild-type	0.04	ALK rearrangements showed good outcomes but lower compared to EGFR mutations.
PD-L1 Positive (N=90)	60%	20%	20 months	PD-L1 vs. Wild-type	0.03	PD-L1 positive group showed moderate results, worse than EGFR but better than wild-type.
Wild-type (N=70)	45%	25%	16 months	Wild-type vs. all other groups	0.01	Wild-type showed the lowest response rate and the worst survival outcomes.

The One-Way Multiple Range Analysis (Tukey's HSD) test identified significant differences in the response rate, severe adverse events, and OS across the groups. The best response rate (70%) and overall survival (24 months) were found in the EGFR mutation group. Patients with ALK (65%) and PD-L1 positive (60%) had a significant response rate, which was significantly better than the other groups. The wild-type group had the lowest response rate of 45% and the worst overall survival at 16 months, indicating the limited effectiveness of standard chemotherapy. Moreover, the incidence of severe adverse events was also highest in the wild-type group at 25% and lowest in the EGFR mutation group at 10%, which again indicates better

tolerability of targeted therapies. These findings point out that the biomarker-driven therapies, especially targeting EGFR mutations, significantly improve the treatment outcomes as compared to chemotherapy in NSCLC patients.

DISCUSSION

This study aimed at assessing the biomarker-based, personalized therapies with respect to NSCLC in terms of treatment outcomes, highlighting actionable genetic alterations such as EGFR, ALK, and PD-L1. Overall, the analysis showed that these targeted therapies along with immunotherapy significantly outscored traditional chemotherapy in terms of treatment efficacy, response rates, and overall survival (OS) while being less toxic with fewer adverse effects. These results demonstrate the promise of tailored treatment approaches to NSCLC and emphasize the importance of biomarkers for the maximization of therapeutic interventions.

Response Rates and Survival Outcomes

The analysis showed that patients with EGFR mutations had the highest response rates (70%) and the best OS (24 months). These results are in line with previous studies that have shown, time and again, the superior efficacy of EGFR-targeted therapies (e.g., gefitinib, osimertinib) in patients harboring specific EGFR mutations, such as exon 19 deletions and L858R point mutations [41]. The EGFR inhibitors have demonstrated clinical efficacy through efficient blockade of signals that sustain growth in the cancer, providing enhanced clinical benefit than the standard chemotherapy with platinum compounds. A remarkably high response rate and the potential for prolonged survival noted in this arm are also comparable to some recent pivotal studies in the area like IPASS and LUX-Lung, showing better PFS as well as survival with the treatment using EGFR TKIs [42].

While EGFR-mutant patients experienced the best outcomes, ALK-rearranged and PD-L1-positive groups also showed favorable results compared to wild-type patients. The ALK-rearranged group, with an average response rate of 65% and OS of 22 months, responded well to ALK inhibitors like crizotinib and alectinib, consistent with previous research. Similarly, the PD-L1-positive group, treated with PD-1 inhibitors such as pembrolizumab and nivolumab, had a moderate response rate (60%) and OS (20 months). This group benefited from immunotherapies that enhance the immune system's ability to recognize and destroy tumor cells, which has been demonstrated in numerous studies as an effective treatment for advanced NSCLC.

On the other hand, wild-type patients, who did not have actionable mutations or PD-L1 expression, had the poorest response rate (45%) and survival outcomes (16 months). This outcome is expected, as these patients are typically treated with platinum-based chemotherapy, which, although standard, has limited efficacy in comparison to targeted therapies and immunotherapies [43].

The analysis of adverse events also highlighted significant differences between treatment groups. The wild-type group experienced the highest frequency of severe adverse events (25%), which is consistent with the toxic side effects commonly associated with platinum-based chemotherapy. These side effects can include severe gastrointestinal symptoms, hematologic toxicities, and neurotoxicity, all of which contribute to treatment discontinuation and reduced patient quality of life . In contrast, the EGFR-mutant group had the lowest incidence of severe adverse events (10%), indicating the relatively better tolerability of EGFR-targeted therapies. This finding corroborates previous reports that have shown EGFR TKIs to be well-tolerated, with side effects generally limited to mild rashes and diarrhea, which can be managed effectively [44].

The rates of severe adverse events in the ALK-rearranged and PD-L1-positive groups were moderate 15% and 20%, respectively, which falls into the expectations of targeted therapies and immunotherapies. ALK inhibitors are well tolerated but can cause visual disturbances and abnormal elevation of liver enzymes. On the other hand, PD-1 inhibitors are known to cause immune-related adverse events such as pneumonitis, colitis, or rash. However, with regard to response rates and survival outcomes, the benefits of such therapies clearly outweigh the dangers of potential side effects.

The success rate of biomarker testing was high across all groups, with no significant differences in testing accuracy: 95% for EGFR mutations, 90% for ALK rearrangements, and 98% for PD-L1 expression. This underlines the importance of reliable and accessible biomarker testing in clinical practice. The ability to identify specific genetic alterations allows for more personalized treatment plans that can significantly improve patient outcomes. The use of NGS (Next-Generation Sequencing), PCR, and FISH technologies to detect EGFR mutations, ALK rearrangements, and PD-L1 expression has become well established and is now a standard of care in the treatment of NSCLC.

Since the success rates of biomarker testing are pretty high and so is the comparison in treatment results, it proves that personalized treatments do offer greater clinical benefit compared to standard chemotherapy. Implementation of biomarker testing in a regular clinical routine would allow for appropriate identification of who may benefit more from targeted treatments or immunotherapy to enhance their overall survival along with quality of life [45].

Despite the promising results, this study has several limitations. For instance, sample size for each group, though adequate, might have been larger to enhance

statistical power and generalizability. Further, the study concentrated mainly on advanced-stage NSCLC (stage IIIB-IV), so results may not apply to patients with early-stage disease, who might have different therapeutic responses. Another limitation is that treatment resistance can occur in some patients, especially in those with EGFR mutations who may develop T790M resistance mutations after prolonged use of EGFR inhibitors [37]. Further studies with larger cohorts and long-term follow-up are needed to assess the durability of the response and to explore strategies for overcoming resistance.

CONCLUSION

In particular, this research underscores the paramount position of biomarker-based personal treatments in managing non-small cell lung cancer (NSCLC), with regard to patients with actionable genetic mutations including EGFR, ALK, and PD-L1. Personalized treatments like EGFR inhibitors, ALK inhibitors, and PD-1 inhibitors dramatically surpass traditional chemotherapy by their superior response rates, overall survival, and adverse event profiles. The best response rates (70%) and survival outcomes of 24 months were seen in the patients harboring EGFR mutations, thereby indicating the high efficacy of the targeted therapies. The other patients with ALK rearrangements and PD-L1 positivity also responded well to their respective therapies. ALK inhibitors and PD-1 inhibitors had shown promising results in comparison to the wild-type group treated with standard chemotherapy.

Moreover, the study indicated that biomarker testing is of importance for selecting patients most likely to be treated with certain targeted therapies. Success rates are so high in cases of EGFR mutation testing, ALK rearrangement detection, and PD-L1 expression testing, making it increasingly important to implement comprehensive biomarker profiling into daily clinical practice. Biomarker tests, reliable and accessible, will allow tailoring of clinical management to include molecular characteristics within the tumor-optimized therapeutic outcomes to minimize unnecessary toxicities associated with traditional chemotherapy.

The study found that targeted therapies and immunotherapies significantly reduced adverse events in patients. Patients with EGFR mutations had fewer side effects than those treated with platinum-based chemotherapy, which is associated with a high rate of toxicities, including gastrointestinal disturbances, hematological disturbances, and neurotoxicity. This discovery further supports the idea that tailored therapies are more effective and more tolerable by patients, therefore improving their quality of life.

However, the study also highlighted some important limitations. The sample size, although adequate for statistical analysis, could have been larger, particularly in rare biomarker groups, to provide more robust conclusions. Additionally, while the study focused on advanced-stage NSCLC, future research should explore the benefits of personalized therapies in earlier stages of cancer to determine whether these treatments are equally effective in less advanced disease. Another important consideration is the potential for treatment resistance, particularly with EGFR inhibitors, where mutations like T790M may develop, leading to treatment failure. Addressing this challenge through combination therapies or the development of newer inhibitors will be crucial in further improving patient outcomes.

In summary, this study further strengthens the transformative potential of biomarker-driven treatment strategies in the management of NSCLC. Targeted therapies and immunotherapies bring about significant improvements in response rates, overall survival, and tolerability compared to conventional chemotherapy. The more that is understood about the molecular underpinnings of NSCLC, the more the personalized treatment approaches will evolve, thus providing more effective, individualized, and less toxic options for patients. Routine biomarker testing should be incorporated into clinical practice for the future of NSCLC treatment so that each patient receives the most appropriate and effective therapy based on their unique tumor characteristics. In this regard, improvement in survival will not only be noted, but quality of life will also be enhanced as a way to shape a more personalized and precise future for cancer care.

REFERENCES

1. Wang, M., Herbst, R. S., & Boshoff, C. (2021). Toward personalized treatment approaches for non-small-cell lung cancer. *Nature medicine*, *27*(8), 1345-1356. https://doi.org/10.1038/s41591-021-01450-2
2. Kalia, M. (2015). Biomarkers for personalized oncology: recent advances and future challenges. *Metabolism*, *64*(3), S16–S21. https://doi.org/10.1016/j.metabol.2014.10.027
3. Okimoto, R. A., & Bivona, T. (2014). Recent advances in personalized lung cancer medicine. *Personalized Medicine*, *11*(3), 309–321. https://doi.org/10.2217/pme.14.19
4. Domvri, K., Zarogoulidis, P., Darwiche, K., Browning, R. F., Li, Q., Turner, J. F., Kioumis, I., Spyratos, D., Porpodis, K.,

Papaiwannou, A., Tsiouda, T., Freitag, L., & Zarogoulidis, K. (2013). Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy. *Journal of Cancer*, *4*(9), 736-754. https://doi.org/10.7150/jca.7734

5. Maciejko, L., Smalley, M., & Goldman, A. (2017). Cancer immunotherapy and personalized medicine: Emerging technologies and biomarker based approaches. *Journal of Molecular Biomarkers & Diagnosis*, *08*(05). https://doi.org/10.4172/2155-9929.1000350
6. Harada, K., & Ono, S. (2024). Background and clinical significance of biomarker-based patient enrichment in non-small-cell lung cancer drug development. *Scientific Reports*, *14*(1). https://doi.org/10.1038/s41598-024-57556-3
7. Fang, B., Mehran, R. J., Heymach, J. V., & Swisher, S. G. (2015). Predictive biomarkers in precision medicine and drug development against lung cancer. *Chinese Journal of Cancer*, *34*(3). https://doi.org/10.1186/s40880-015-0028-4
8. Restrepo, J. C., Martínez Guevara, D., Pareja López, A., Montenegro Palacios, J. F., & Liscano, Y. (2024). Identification and application of emerging biomarkers in treatment of non-small-Cell lung cancer: Systematic review. *Cancers*, *16*(13), 2338. https://doi.org/10.3390/cancers16132338
9. Soldera, S. V., & Leighl, N. B. (2017). Update on the treatment of metastatic squamous non-small cell lung cancer in new era of personalized medicine. *Frontiers in Oncology*, *7*. https://doi.org/10.3389/fonc.2017.00050
10. Moreira, A. L., & Eng, J. (2014). Personalized therapy for lung cancer. *Chest*, *146*(6), 1649-1657. https://doi.org/10.1378/chest.14-0713
11. Habib, S., Vogel, T., Anli, X., & Thorne, E. (2024). How does generative artificial intelligence impact student creativity? *Journal of Creativity*, *34*(1), 100072. https://doi.org/10.1016/j.yjoc.2023.100072
12. La Thangue, N. B., & Kerr, D. J. (2011). Predictive biomarkers: A paradigm shift towards personalized cancer medicine. *Nature Reviews Clinical Oncology*, *8*(10), 587-596. https://doi.org/10.1038/nrclinonc.2011.121
13. Kim, E. S., Herbst, R. S., Wistuba, I. I., Lee, J. J., Blumenschein, G. R., Tsao, A., Stewart, D. J., Hicks, M. E., Erasmus, J., Gupta, S., Alden, C. M., Liu, S., Tang, X., Khuri, F. R., Tran, H. T., Johnson, B. E., Heymach, J. V., Mao, L., Fossella, F., & Kies, M. S. (2011). The BATTLE Trial: Personalizing Therapy for Lung Cancer. *Cancer Discovery*, *1*(1), 44–53. https://doi.org/10.1158/2159-8274.cd-10-0010
14. Shimizu, J., Masago, K., Saito, H., Nishino, K., Kurata, T., Itoh, Y., Yoshimura, Y., Yabuki, Y., & Dosaka-Akita, H. (2020). Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: A retrospective, multicenter, observational study (the BRAVE study). *Therapeutic Advances in Medical Oncology*, *12*. https://doi.org/10.1177/1758835920904522
15. Gambardella, V., Tarazona, N., Cejalvo, J. M., Lombardi, P., Huerta, M., Roselló, S., Fleitas, T., Roda, D., & Cervantes, A. (2020). Personalized medicine: Recent progress in cancer therapy. *Cancers*, *12*(4), 1009. https://doi.org/10.3390/cancers12041009
16. Galot, R., Le Tourneau, C., Guigay, J., Licitra, L., Tinhofer, I., Kong, A., Caballero, C., Fortpied, C., Bogaerts, J., Govaerts, A., Staelens, D., Raveloarivahy, T., Rodegher, L., Laes, J., Saada-Bouzid, E., & Machiels, J. (2018). Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach. *Annals of Oncology*, *29*(12), 2313-2327. https://doi.org/10.1093/annonc/mdy452
17. Cortiana, V., Abbas, R. H., Chorya, H., Gambill, J., Mahendru, D., Park, C. H., &

Leyfman, Y. (2024). Personalized medicine in pancreatic cancer: The promise of biomarkers and molecular targeting with Dr. Michael J. Pishvaian. *Cancers*, *16*(13), 2329. https://doi.org/10.3390/cancers16132329

18. Horne, A., Crawford, H., Dempsey, C., & Faivre-Finn, C. (2024). P3.08F.04 developing circulating and imaging biomarkers towards personalised radiotherapy in lung cancer: An update on the vigilance study. *Journal of Thoracic Oncology*, *19*(10), S339. https://doi.org/10.1016/j.jtho.2024.09.610
19. Schwaederle, M., Zhao, M., Lee, J. J., Lazar, V., Leyland-Jones, B., Schilsky, R. L., Mendelsohn, J., & Kurzrock, R. (2016). Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms. *JAMA Oncology*, *2*(11), 1452. https://doi.org/10.1001/jamaoncol.2016.2129
20. De Jong, D., Das, J. P., Ma, H., Pailey Valiplackal, J., Prendergast, C., Roa, T., Braumuller, B., Deng, A., Dercle, L., Yeh, R., Salvatore, M. M., & Capaccione, K. M. (2023). Novel targets, novel treatments: The changing landscape of non-small cell lung cancer. *Cancers*, *15*(10), 2855. https://doi.org/10.3390/cancers15102855
21. Seijo, L. M., Peled, N., Ajona, D., Boeri, M., Field, J. K., Sozzi, G., Pio, R., Zulueta, J. J., Spira, A., Massion, P. P., Mazzone, P. J., & Montuenga, L. M. (2019). Biomarkers in lung cancer screening: Achievements, promises, and challenges. *Journal of Thoracic Oncology*, *14*(3), 343-357. https://doi.org/10.1016/j.jtho.2018.11.023
22. Mitsudomi, T., & Suda, K. (2013). Development of personalized treatments in lung cancer: Focusing on the EGFR mutations and beyond. *Lung Cancer: Targets and Therapy*, 43. https://doi.org/10.2147/lctt.s49603
23. Hirsh, V., & Melosky, B. (Eds.). (2018). *Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine*. Frontiers Media SA. https://doi.org/10.3389/978-2-88945-397-9
24. Suri, C., Swarnkar, S., Bhaskar, L., & Verma, H. K. (2024). Non-coding RNA as a biomarker in lung cancer. *Non-Coding RNA*, *10*(5), 50. https://doi.org/10.3390/ncrna10050050
25. Garon, E. B., Abarca, P. A., Strunck, J. L., Nameth, D., Neumann, C., Wolf, B., Kim, K. Y., Marx, C., & Elashoff, R. M. (2015). Clinical trials in non-small cell lung cancer with biomarker-driven treatment allocation: Ready or not, here we come. *Critical Reviews in Oncogenesis*, *20*(5-6), 339-347. https://doi.org/10.1615/critrevoncog.v20.i5-6.70
26. Chung, C., & Umoru, G. (2024). Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation. *Journal of Oncology Pharmacy Practice*. https://doi.org/10.1177/10781552241242684
27. Dakal, T. C., Dhakar, R., Beura, A., Moar, K., Maurya, P. K., Sharma, N. K., Ranga, V., & Kumar, A. (2024). Emerging methods and techniques for cancer biomarker discovery. *Pathology - Research and Practice*, *262*, 155567. https://doi.org/10.1016/j.prp.2024.155567
28. Ujhazy, P., & Herbst, R. (2012). Personalized therapy. *Journal of Thoracic Oncology*, *7*(12), S401-S403. https://doi.org/10.1097/jto.0b013e31826df27c
29. Nadler, E., Vasudevan, A., Wang, Y., & Ogale, S. (2022). Real-world patterns of biomarker testing and targeted therapy in de Novo metastatic non-small cell lung cancer patients in the US oncology network. *Cancer Treatment and Research Communications*, *31*, 100522. https://doi.org/10.1016/j.ctarc.2022.100522
30. Wistuba, I. I., Gelovani, J. G., Jacoby, J. J., Davis, S. E., & Herbst, R. S. (2011). Methodological and practical challenges for

personalized cancer therapies. *Nature Reviews Clinical Oncology*, *8*(3), 135-141. https://doi.org/10.1038/nrclinonc.2011.2

31. Simon, G. R. (2008). Individualizing chemotherapy for non-small cell lung cancer (NSCLC) in the adjuvant and advanced setting: Current status and future directions. *Current Treatment Options in Oncology*, *9*(4-6), 300-312. https://doi.org/10.1007/s11864-008-0075-z
32. Pellino, G., Gallo, G., Pallante, P., Capasso, R., De Stefano, A., Maretto, I., Malapelle, U., Qiu, S., Nikolaou, S., Barina, A., Clerico, G., Reginelli, A., Giuliani, A., Sciaudone, G., Kontovounisios, C., Brunese, L., Trompetto, M., & Selvaggi, F. (2018). Noninvasive biomarkers of colorectal cancer: Role in diagnosis and personalised treatment perspectives. *Gastroenterology Research and Practice*, *2018*, 1-21. https://doi.org/10.1155/2018/2397863
33. Gridelli, C., Rossi, A., Carbone, D. P., Guarize, J., Karachaliou, N., Mok, T., ... & Rosell, R. (2015). Non-small-cell lung cancer. *Nature reviews Disease primers*, *1*(1), 1-16. https://doi.org/10.1038/s41572-024-00562-6
34. Naseer, M., Iftikhar, S., Shahid, R., Haq, E. U., Abbas, S., Ali, A., & Azhar, S. (2024). Integrating Biochemistry and Oncology: Proteomics-driven Cancer Biomarker Discoveries, Transforming Early Detection and Personalized Therapy. *Pak-Euro Journal of Medical and Life Sciences*, *7*(3), 375-384. https://readersinsight.net/PJMLS/article/view/3123
35. Kaneda, H., Yoshida, T., & Okamoto, I. (2013). Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment. *Cancer Management and Research, 5*, 91–101. https://doi.org/10.2147/CMAR.S32973
36. Stinchcombe, T. E. (2020). Current management of *RET* rearranged non-small cell lung cancer. *Therapeutic Advances in Medical Oncology*, *12*. https://doi.org/10.1177/1758835920928634
37. Kästner, A., Kron, A., Van den Berg, N., Moon, K., Scheffler, M., Schillinger, G., Pelusi, N., Hartmann, N., Rieke, D. T., Stephan-Falkenau, S., Schuler, M., Wermke, M., Weichert, W., Klauschen, F., Haller, F., Hummel, H., Sebastian, M., Gattenlöhner, S., Bokemeyer, C., … Hoffmann, W. (2024). Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: A historical cohort analysis. *The Lancet Regional Health - Europe*, *36*, 100788. https://doi.org/10.1016/j.lanepe.2023.100788
38. Wigle, D. A. (2011). Personalized therapy for non–small cell lung cancer: Hype or clinical reality? *Seminars in Thoracic and Cardiovascular Surgery*, *23*(1), 30-35. https://doi.org/10.1053/j.semtcvs.2011.03.007
39. Tan, C., Gilligan, D., & Pacey, S. (2015). Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. *The Lancet Oncology*, *16*(9), e447-e459. https://doi.org/10.1016/s1470-2045(15)00246-6
40. Yuan, M., Zhao, Y., Arkenau, H., Lao, T., Chu, L., & Xu, Q. (2022). Signal pathways and precision therapy of small-cell lung cancer. *Signal Transduction and Targeted Therapy*, *7*(1). https://doi.org/10.1038/s41392-022-01013-y
41. Gridelli, C. (2012). Personalized medicine in the treatment of advanced nonsmall cell lung cancer. *Current Opinion in Oncology*, *24*(2), 115-116. https://doi.org/10.1097/cco.0b013e32834ea6d7
42. Gutierrez, M., Lam, W., Hellmann, M. D., Gubens, M. A., Aggarwal, C., Tan, D. S., Felip, E., Chiu, J. W., Lee, J., Yang, J. C., Garon, E. B., Finocchiaro, G., Ahn, M., Luft, A., Landers, G. A., Basso, A., Ma, H., Kobie, J., Palcza, J., … Herbst, R. S. (2023). Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: Phase 2 KEYNOTE-495/KeyImPaCT trial interim results. *Nature Medicine*, *29*(7), 1718-

1727. https://doi.org/10.1038/s41591-023-02385-6

43. Dang, T. O., Ogunniyi, A., Barbee, M. S., & Drilon, A. (2015). Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. *Expert Review of Anticancer Therapy*, *16*(1), 13-20. https://doi.org/10.1586/14737140.2016.1123626

44. Bepler, G. (2007). Phase II pharmacogenomics-based adjuvant therapy trial in patients with non–small-cell lung cancer: Southwest oncology group trial 0720. *Clinical Lung Cancer*, *8*(8), 509-511. https://doi.org/10.3816/clc.2007.n.039

45. Hirsch, F. R., & Kim, C. (2024). The importance of biomarker testing in the treatment of advanced non-small cell lung cancer: A podcast. *Oncology and Therapy*, *12*(2), 223-231. https://doi.org/10.1007/s40487-024-00271-w